New insider activity at NewAmsterdam Pharma Company ( (NAMS) ) has taken place on August 25, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSO Kastelein Johannes Jacob Pieter has sold 100,000 shares of NewAmsterdam Pharma Company stock, amounting to a transaction worth $2,471,639.
Recent Updates on NAMS stock
In the last 24 hours, NewAmsterdam Pharma Company has seen significant developments that have impacted its stock outlook. Wells Fargo initiated coverage with an Overweight rating, citing the potential of cholesteryl ester transfer protein inhibition as a promising area for lipid-lowering treatments, which could represent a multibillion-dollar opportunity. The company’s drug, obicetrapib, is built on the foundations of previous CETP inhibitors and is supported by the ongoing PREVAIL study. Additionally, the European Medicines Agency has validated the Marketing Authorization Application for obicetrapib, marking a critical step towards its potential approval in Europe. Despite these positive developments, the stock’s valuation is tempered by financial challenges, such as lack of profitability and negative cash flows, which have led to a Hold rating with a $23.60 price target from another analyst. The company’s growth potential in Alzheimer’s and cardiovascular treatments, however, offers a compelling long-term opportunity.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The overall score reflects strong technical momentum and positive corporate events, which are offset by financial performance challenges and valuation concerns. The company’s strategic advances in drug development and regulatory milestones are significant positives, but profitability and valuation remain key risks.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
YTD Price Performance: -3.70%
Average Trading Volume: 884,972
Technical Sentiment Signal: Buy
Current Market Cap: $2.82B